TELL A FRIEND ABOUT OSMOPREP Mail a Friend

Send a friend a link to this page.

Your Name:
Your E-mail:
Friend's Name:
Friend's E-mail:

Send me a copy of this e-mail
Send me updates about OsmoPrep

ARE YOU AT RISK FOR COLON CANCER?

TAKE THE RISK ASSESSMENT NOW

Print this page:

Font Size:

The Tablet Prep®

OsmoPrep Tablets are indicated to cleanse the colon as a preparation for colonoscopy in adults 18 years of age or older. This virtually tasteless tablet formulation can be taken with any clear liquid and has been demonstrated to improve patient compliance and satisfaction through improved patient tolerability.²

97% of patients were fully compliant with the OsmoPrep regimen¹
95% of patients were rated either excellent or good for overall colon cleansing¹
Low incidence of gastrointestinal side effects³
95% of patients would choose OsmoPrep again¹

Discover more about OsmoPrep Tablets and how they might benefit your patients.

Download the Patient Instructions.

English

Spanish

Download a copy of The OsmoPrep Colonoscopy Preparation Brochure.

English

Download full Prescribing Information and Medication Guide for OsmoPrep.

OsmoPrep Prescribing Information

OsmoPrep Medication Guide

OsmoPrep Spanish Prescribing Information
and Medication Guide
Additional safety information: www.warninginfoforosmoprepandvisicol.com.

View the physician education program, "Advances in the
Evidence-Based Management of Patients Prior to Colonoscopy,"
presented by Dr. Douglas Rex.

View the physician education program, "Improving the Detection of
      Colorectal Neoplasms," in which Drs. Douglas Rex and
      Roy Soetikno discuss the detection of nonpolypoid lesions during
      colonoscopy and the importance of proper bowel preparation.

To order samples or for more information about OsmoPrep, contact the Salix Pharmaceuticals Customer Care Center at 1-866-669-7597.

Important Safety Information about OsmoPrep

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

Please see full Prescribing Information for OsmoPrep, including BOXED WARNING.

OsmoPrep^® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OsmoPrep is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OsmoPrep.

OsmoPrep is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OsmoPrep be advised to adequately hydrate before, during, and after the use of OsmoPrep.

Rex DK, Schwartz H, Goldstein M, et al. Safety and colon-cleansing efficacy of a new residue-free formulation of sodium phosphate tablets. Am J Gastroenterol. 2006;101:2594-2604.
Data on file, Salix Pharmaceuticals, Inc.
OsmoPrep Tablets [package insert]. Morrisville, NC: Salix Pharmaceuticals, Inc; 2007.